Global Interstitial Cystitis Drugs Market - 2022-2029

Global Interstitial Cystitis Drugs Market - 2022-2029

Market Overview

The global interstitial cystitis drugs market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Interstitial cystitis is a persistent illness that causes pressure in the bladder and bladder and pelvic pain. The soreness might range from minor to severe. The disorder is part of the painful bladder syndrome range of diseases. Although there's no cure, medications and other therapies may offer relief.

Market Dynamics

Increasing Investigational treatments for the treatment of BPS/IC is expected to drive market growth.

The plasma membrane contains most of the transient receptor potential (TRP) channels. They are in charge of transporting calcium, magnesium, and metal ions across the cell membrane. Many physiological systems, including sensory functions (pain and heat perception), hemostatic functions, vasomotor activities, and muscular contraction, rely on it. For instance, Intravesical capsaicin therapy has been used effectively to treat detrusor overactivity (DOA) in patients with neurogenic bladder.

Moreover, the recent innovation of specialized financing programs to assist rare illness research has the potential to boost basic scientific and clinical research in this field. Rather than research on more common diseases that the scientific community is more familiar with, rare illness research has been recognized as requiring unique research approaches such as data gathering, data processing, and international collaborations. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Lack of approved drugs, high treatment costs, side effects of current medications, and a poor diagnostic rate of interstitial cystitis throughout the forecast period due to a lack of licensed therapies and low therapeutic efficacy of symptomatic drugs hamper the market.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The coronavirus, or COVID-19, the outbreak began in Wuhan, China, and has now expanded across continents, affecting a wide range of businesses. IC's persistent pain feelings caused by IC have been linked to psychological issues like anxiety and sadness. Furthermore, the COVID-19 epidemic exacerbated IC patients' distress by inducing psychological symptoms such as dread, despair, boredom, frustration, and anger. A multidisciplinary approach provides tailored treatment for IC patients by delivering a web-mediated counseling intervention for patients and their caregivers. This may support a relationship-based reform process that improves one's quality of life.

Additionally, the pandemic interrupts the supply chain. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Dimethyl sulfoxide (DMSO) segment is expected to hold the largest market share in interstitial cystitis drugs market

The dimethyl sulfoxide (DMSO)segment is expected to dominate in 2021. The segment benefits because it is the latest treatment for interstitial cystitis, and it is believed to reduce swelling and pain due to interstitial cystitis. It may improve blood supply to the treated area. Moreover, On 4th November 2021, the US Food and Drug Administration (FDA) approved Dimethyl sulfoxide (DMSO) to treat interstitial cystitis/bladder pain syndrome (IC/BPS). Therefore, it has increased the demand for the drug. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global interstitial cystitis drugs market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of interstitial cystitis, rise in research funding, advances in interstitial diagnostic imaging of interstitial cystitis and high adoption of interstitial cystitis drugs in the region are some of the factors the market is expected to boost in the forecast period. For instance, Interstitial cystitis (IC) is common in the U.S. was reported to be 5,894,905 in 2018. In contrast, the condition may affect between 3 million and 8 million women and between 1 million and 4 million men in the United States in 2020. Moreover, recent bladder wall and brain MRI developments could revolutionize our understanding and treatment of people with IC/BPS. T1-weighted MRI and fMRI with high resolution can reveal abnormalities in central processing in persistent pelvic discomfort. CE-MRI of the bladder wall can objectively distinguish three distinct IC/BPS entities pelvic hypersensitivity, IC/BPS, and IC/BPS with Hunner's lesions. Such objective classification can help doctors choose the right patients for medications that target chronic inflammation in the bladder wall and lessen the dependence on subjective results to predict the efficacy and safety of new treatments. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the interstitial cystitis drugs market are Perrigo Company plc., Bayer HealthCare LLC, GlaxoSmithKline (GSK), Inc., Janssen Pharmaceuticals, Inc., Mallinckrodt Inc., FemmePharma Consumer Healthcare, Tyros Biopharma Inc. and Sandoz Inc.

Janssen Pharmaceuticals, Inc..:

Overview:

Janssen Pharmaceuticals is a completely owned subsidiary of Johnson & Johnson with headquarters in Beerse, Belgium. Paul Janssen launched the company in 1953. It works on mental disease, neurological problems, anesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies, and cancer, among other things. The Johnson & Johnson Company Ortho-McNeil-Janssen group now includes Janssen and Ortho-McNeil Pharmaceutical.

­Product Portfolio:

ELMIRON (‍pentosan polysulfate sodium‍)‍: ELMIRON is a prescription medicine that treats bladder pain or discomfort associated with interstitial cystitis.

Why Purchase the Report?

Visualize the composition of the interstitial cystitis drugs market segmentation by drug class, route of administration, distribution channel and region highlighting the key commercial assets and players.

Identify commercial opportunities in interstitial cystitis drugs market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of interstitial cystitis drugs market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global interstitial cystitis drugs market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers